Imatinib Completed Phase 2 Trials for Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT00510653Gleevec Study for Patients With Ovarian Cancer
NCT00039585Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor